Belpointe Asset Management’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
Other funds holding ALNY
Belpointe Asset Management's ALNY Position: Q2 2023 in Review
Belpointe Asset Management sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2023, closing a stake of 105 shares — an estimated $21K sold.
Belpointe Asset Management first reported a position in ALNY in Q1 2022 and held it in 3 quarters. The position peaked at $110K in Q1 2022. 476 funds tracked by Wall St. Rank hold ALNY as of Q2 2023.
- Belpointe Asset Management reported no remaining Alnylam Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
- Belpointe Asset Management sold 105 Alnylam Pharmaceuticals shares in Q2 2023, an estimated $21K.
- Belpointe Asset Management first reported a position in Alnylam Pharmaceuticals in Q1 2022 and held it in 3 quarters.
- Belpointe Asset Management's Alnylam Pharmaceuticals position peaked at $110K in Q1 2022.
- 476 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2023.
Based on Belpointe Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.